查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1883237

全球载体筛检市场

Carrier Screening
出版日期: | 出版商: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 英文 173 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

全球病毒带因者筛检市场预计到2030年将达到78亿美元

全球带因者筛检市场规模在2024年估计为33亿美元，预计到2030年将达到78亿美元，在分析期间（2024-2030年）内复合年增长率（CAGR）为15.6%。本报告分析的细分市场之一－遗传疾病细分市场，预计复合年增长率将达到18.8%，并在分析期结束时达到30亿美元。囊肿纤维化细分市场预计在分析期间内复合年增长率将达到16.5%。

美国市场规模估计为8.659亿美元，而中国市场预计将以21.5%的复合年增长率成长。

预计到2024年，美国病毒带因者筛检市场规模将达8.659亿美元。作为世界第二大经济体，中国预计到2030年市场规模将达到19亿美元，在2024年至2030年的分析期间内，复合年增长率（CAGR）将达到21.5%。其他值得关注的区域市场包括日本和加拿大，预计在分析期内，这两个国家的复合年增长率将分别达到10.9%和13.2%。在欧洲，德国预计将以约12.2%的复合年增长率成长。

全球载体筛检市场—主要市场趋势与驱动因素概述

为什么携带者筛检是现代医学的重要工具？

带因者筛检是一项重要的基因检测流程，它可以帮助个人和夫妻确定是否拥有者某些遗传疾病的基因，即使他们本身没有任何症状。这项筛检在生育计画中发挥重要作用，使准父母能够评估他们将囊肿纤维化、戴-萨克斯病和镰状细胞贫血等遗传疾病遗传给子女的风险。随着人们对遗传健康的认识不断提高，携带者筛检已成为孕前和产前保健的基石，使人们有机会做出知情的生育决定。在个人化医疗和预防性医疗保健蓬勃发展的时代，携带者筛检为早期发现和主动健康管理提供了一种强大的工具，使家庭能够在怀孕前降低风险。携带者筛检的价值在于它提供的详细基因信息，帮助人们了解自身的基因相容性。这些资讯可以指南夫妻就遗传咨询、辅助生殖技术（例如体外受精（IVF）结合基因检测）以及其他生育策略做出明智的选择。随着基因技术的进步和可筛检疾病的增加，携带者筛检正变得越来越普遍，使更多家庭能够获得重要的基因讯息，筛检预防严重的传播。

技术创新如何改进了带因者筛检？

技术创新显着提升了携带者筛检的效率，使其速度更快、成本更低、覆盖范围更广。其中一项最具突破性的进展是次世代定序（NGS），它能够同时分析多个基因，从而降低成本并扩大筛检疾病的范围。 NGS 使得更广泛、更详细的带因者筛检方案成为可能，一次检测即可检测数百种遗传疾病。这大大提高了携带者筛检的准确性和覆盖范围，使夫妻能够全面了解自身的遗传风险，并就生育计划做出明智的决定。家用基因检测套组的广泛普及也彻底改变了携带者筛检的途径，人们可以在家中采集 DNA 样本，并在经认证的实验室进行分析。这些试剂盒的便利性和易用性使得更多人能够进行基因检测，不受居住限制。基于生物资讯学的遗传数据分析技术的进步，以及人工智慧（AI）的融合应用，进一步提高了检测结果的准确性，减少了人为误差的可能性，并提供了更快、更可靠的遗传资讯。随着人工智慧的发展，预计它将在提高携带者筛检结果的准确性和预测能力方面发挥更重要的作用，进一步扩大其在生殖医学领域的应用范围。

哪些新兴趋势正在影响病毒携带者筛检市场？

随着技术进步和医疗重点的转变，基因检测方法也在不断变化，目前有几个关键趋势正在影响携带者筛检市场。其中一个关键趋势是向「扩展型带因者筛检」的转变，即在检测项目中纳入更广泛的遗传疾病。传统的带因者筛检仅关注少数几种疾病，而如今，技术进步使得单次检测即可涵盖数百种遗传疾病。这种扩展型筛检方法越来越受欢迎，因为它能更全面地了解遗传风险，使个人及其医疗保健提供者能够做出更明智的决定。另一个新兴趋势是将携带者筛检融入个人化医疗。随着医疗保健环境向个人化治疗方案转变，基因检测不仅用于生育计划，还用于疾病预防。此外，携带者筛检正日益被推荐为普遍服务，适用于所有计划生育的人群，无论其种族背景或家族病史如何。这种普及带因者筛检的趋势使得更多高风险夫妻能够及早被发现，从而采取积极措施，降低将严重遗传疾病遗传给后代的可能性。值得注意的是，遗传咨询的角色正随着携带者筛检的发展而不断扩大。随着携带者筛检结果日益复杂，遗传咨询师在解读结果、帮助人们了解其对生殖健康的影响方面发挥着至关重要的作用。此外，诸如线上入口网站和远端医疗等数位化工具的普及，使得携带者筛检和遗传咨询服务更容易远端获取，进一步扩大了这些重要医疗服务的覆盖范围。

哪些因素正在推动病毒携带者筛检市场的成长？

携带者筛检市场的成长受多种因素驱动，主要包括基因技术的进步、人们对遗传疾病认知的提高以及医疗实践的不断发展。其中一个关键驱动因素是人们对遗传健康在计划生育中重要性的认识不断提高。随着越来越多的人了解遗传在疾病预防中的作用，对携带者筛检的需求显着增长。医疗保健提供者和遗传咨询师的教育工作正在将携带者筛检确立为孕前和孕期保健的重要组成部分，尤其对于那些有将遗传疾病遗传给后代风险的夫妇而言。基因检测技术的进步，特别是次世代定序（NGS）技术的进步，降低了携带者筛检的成本和周转时间，使其惠及更多人。这些技术进步，加上家用基因检测套组的便利性，降低了进入门槛，鼓励更多人积极主动管理自体生殖健康。此外，医疗保健专业人员建议所有准父母进行普遍带因者筛检，这一趋势透过增加寻求基因检测服务的人数，进一步扩大了市场。监管和保险覆盖范围的改善也是推动市场成长的因素。许多国家现在提供携带者筛检的保险报销，使个人能够更轻鬆地负担得起。此外，随着越来越多的医疗机构将带因者筛检纳入常规生殖健康服务，市场预计将持续成长。最后，个人化和预防性医疗的兴起，使得携带者筛检成为确保子孙后代健康的重要工具。个人化和预防性医疗根据个人的基因谱提供量身定制的医疗服务。这些因素，以及基因研究领域的不断创新，正在推动携带者筛检在全球范围内的持续成长和广泛应用。

部分：

检测类型（分子筛检、生化筛检）；疾病类型（遗传性疾病、囊肿纤维化、脊髓性肌肉萎缩症、高雪氏症、戴-萨克斯病、镰状细胞疾病、其他疾病类型）

受访公司范例

  • 23andMe, Inc.
  • Abbott Laboratories
  • AutoGenomics, Inc.
  • F. Hoffmann-La Roche AG
  • Illumina, Inc.
  • Luminex Corporation
  • Myriad Genetics, Inc.
  • Sequenom, Inc.
  • Thermo Fisher Scientific, Inc.

人工智慧集成

我们正在利用检验的专家内容和人工智慧工具，革新市场和竞争情报分析。

Market Glass, Inc. 并没有采用查询LLM 或产业专用的SLM 的典型方法，而是建立了一个由世界各地领域专家精心策划的内容库，其中包括影片文字稿、部落格、搜寻引擎研究以及大量的公司、产品/服务和市场数据。

关税影响係数

在最新发布的报告中，Market Glass, Inc. 将关税对地理市场的影响纳入考量，并根据公司总部所在国、製造地以及进出口（成品和OEM产品）情况，预测企业竞争格局的变化。这种复杂多变的市场现实将对竞争对手产生多方面的影响，包括销货成本增加、盈利下降和供应链重组，同时也会影响微观和宏观市场动态。

目录

第一章调查方法

第二章执行摘要

  • 市场概览
  • 主要企业
  • 市场趋势和驱动因素
  • 全球市场展望

第三章 市场分析

  • 美国
  • 加拿大
  • 日本
  • 中国
  • 欧洲
  • 法国
  • 德国
  • 义大利
  • 英国
  • 西班牙
  • 俄罗斯
  • 其他欧洲
  • 亚太地区
  • 澳洲
  • 印度
  • 韩国
  • 亚太其他地区
  • 拉丁美洲
  • 阿根廷
  • 巴西
  • 墨西哥
  • 其他拉丁美洲
  • 中东
  • 伊朗
  • 以色列
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 其他中东地区
  • 非洲

第四章 竞赛

简介目录
Product Code: MCP10911

Global Carrier Screening Market to Reach US$7.8 Billion by 2030

The global market for Carrier Screening estimated at US$3.3 Billion in the year 2024, is expected to reach US$7.8 Billion by 2030, growing at a CAGR of 15.6% over the analysis period 2024-2030. Genetic Disorders, one of the segments analyzed in the report, is expected to record a 18.8% CAGR and reach US$3.0 Billion by the end of the analysis period. Growth in the Cystic Fibrosis segment is estimated at 16.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$865.9 Million While China is Forecast to Grow at 21.5% CAGR

The Carrier Screening market in the U.S. is estimated at US$865.9 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.9 Billion by the year 2030 trailing a CAGR of 21.5% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 10.9% and 13.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 12.2% CAGR.

Global Carrier Screening Market - Key Trends and Drivers Summarized

Why Is Carrier Screening a Vital Tool in Modern Healthcare?

Carrier screening is a critical genetic testing process that helps individuals and couples determine if they carry genes for certain inherited disorders, even if they show no symptoms themselves. This screening plays a vital role in reproductive planning, allowing prospective parents to assess the risk of passing genetic conditions, such as cystic fibrosis, Tay-Sachs disease, and sickle cell anemia, to their children. With increasing awareness of genetic health, carrier screening has become a cornerstone of preconception and prenatal care, offering individuals a chance to make informed reproductive decisions. In an era where personalized medicine and preventive care are gaining momentum, carrier screening offers a powerful tool for early detection and proactive health management, allowing families to mitigate risks before conception. The value of carrier screening lies in the detailed genetic insights it provides, helping people understand their genetic compatibility. This information can guide couples toward informed choices such as genetic counseling, assisted reproductive technologies like in vitro fertilization (IVF) with genetic testing, or other reproductive strategies. As genetic technologies advance and the number of conditions identifiable through screening expands, carrier screening is becoming increasingly mainstream, ensuring that more families have access to crucial genetic information that can prevent the transmission of severe disorders.

How Have Technological Advances Enhanced Carrier Screening?

Technological innovations have significantly improved carrier screening, making it faster, more affordable, and more comprehensive. One of the most transformative advancements is next-generation sequencing (NGS), which allows for the analysis of multiple genes simultaneously, increasing the scope of conditions screened for while reducing costs. With NGS, broader and more detailed carrier screening panels are available, testing for hundreds of genetic conditions in a single analysis. This has dramatically improved the accuracy and scope of carrier screening, ensuring that couples receive a comprehensive understanding of their genetic risks and can make well-informed decisions regarding family planning. The rise of at-home genetic testing kits has also revolutionized access to carrier screening, allowing individuals to collect DNA samples at home and send them to certified labs for analysis. The convenience and accessibility of these kits have made it easier for a larger population to undergo genetic testing, regardless of their location. Along with improvements in genetic data analysis through bioinformatics, the integration of artificial intelligence (AI) is further enhancing the precision of test results, reducing the potential for human error, and offering faster, more reliable genetic insights. As AI continues to evolve, it is expected to play an even more critical role in improving the accuracy and predictive power of carrier screening results, further expanding its use in reproductive health.

What Emerging Trends Are Impacting the Carrier Screening Market?

Several important trends are currently shaping the carrier screening market, as advancements in technology and shifting healthcare priorities drive changes in how genetic testing is approached. One of the key trends is the move toward expanded carrier screening, where a broader range of genetic conditions is included in testing panels. Traditionally, carrier screening focused on a limited set of disorders, but advancements in technology now allow for the inclusion of hundreds of genetic conditions in a single test. This expanded screening approach is gaining popularity as it provides a more comprehensive picture of genetic risks, enabling individuals and healthcare providers to make more informed decisions. Another emerging trend is the integration of carrier screening into personalized medicine. As the healthcare landscape shifts toward individualized treatment plans, genetic testing is being used not only for reproductive planning but also to prevent genetic conditions before they develop. In addition, carrier screening is increasingly being recommended as a universal service for all individuals planning to have children, regardless of ethnic background or family history. This trend toward universal carrier screening is helping to ensure that more at-risk couples are identified early, allowing for proactive measures to be taken to reduce the likelihood of transmitting serious genetic conditions to their offspring. The growing role of genetic counseling alongside carrier screening is also noteworthy. As the complexity of carrier screening results increases, genetic counselors are becoming integral to the process, helping individuals interpret results and understand the implications for their reproductive health. Additionally, the rise of digital tools, such as online portals and telemedicine, is making it easier for individuals to access both carrier screening and genetic counseling services remotely, further expanding the reach of this essential healthcare service.

What Factors Are Behind the Growth of the Carrier Screening Market?

The growth in the carrier screening market is driven by several factors, primarily linked to advances in genetic technologies, increased awareness of genetic disorders, and evolving healthcare practices. One of the key drivers is the growing awareness of the importance of genetic health in family planning. As more people understand the role genetics plays in disease prevention, the demand for carrier screening has increased significantly. Educational efforts from healthcare providers and genetic counselors have helped normalize carrier screening as an essential part of preconception and prenatal care, particularly for couples who are at risk of passing on genetic disorders. Advancements in genetic testing technologies, especially next-generation sequencing (NGS), have reduced the cost and turnaround time for carrier screening, making it more accessible to a broader population. These technological improvements, combined with the convenience of at-home genetic testing kits, have lowered barriers to entry, encouraging more individuals to take proactive steps in managing their reproductive health. Moreover, the trend toward universal carrier screening, recommended by healthcare professionals for all prospective parents, has expanded the market by increasing the number of people seeking genetic testing services. Regulatory and insurance coverage improvements have also fueled market growth. Many countries now offer insurance reimbursement for carrier screening, making it more affordable for individuals. Additionally, as more healthcare providers adopt carrier screening as part of routine reproductive health services, the market is poised for continued expansion. Finally, the rise of personalized and preventive medicine, where healthcare is tailored to individual genetic profiles, is positioning carrier screening as a critical tool for ensuring healthier outcomes for future generations. These factors, along with ongoing innovations in genetic research, are driving the continued growth and adoption of carrier screening across the globe.

SCOPE OF STUDY:

The report analyzes the Carrier Screening market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Test Type (Molecular Screening Test, Biochemical Screening Test); Disease Type (Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease, Other Disease Types)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

  • 23andMe, Inc.
  • Abbott Laboratories
  • AutoGenomics, Inc.
  • F. Hoffmann-La Roche AG
  • Illumina, Inc.
  • Luminex Corporation
  • Myriad Genetics, Inc.
  • Sequenom, Inc.
  • Thermo Fisher Scientific, Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Trade Shocks, Uncertainty, and the Structural Rewiring of the Global Economy
    • Global Economic Update
    • Carrier Screening - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Awareness of Genetic Disorders Propels Growth in the Carrier Screening Market
    • Advances in Genomic Technologies Drive the Accuracy and Accessibility of Carrier Screening
    • Growing Adoption of Carrier Screening in Preconception and Prenatal Care Strengthens the Business Case for Genetic Testing
    • Technological Innovations in Next-Generation Sequencing (NGS) Accelerate Demand for Comprehensive Carrier Screening
    • Rising Incidence of Inherited Genetic Disorders Spurs Market Growth in Carrier Screening
    • Growing Demand for Personalized Medicine Generates Opportunities for Carrier Screening in Tailored Healthcare
    • Integration of AI and Data Analytics in Genetic Testing Enhances Efficiency and Interpretation of Carrier Screening Results
    • Rising Healthcare Expenditure and Insurance Coverage for Genetic Testing Sustain Growth in Carrier Screening Services
    • Expanding Use of Carrier Screening in Fertility Treatments Drives Demand in Assisted Reproductive Technology (ART)
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Genetic Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 2: World Historic Review for Genetic Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 3: World 15-Year Perspective for Genetic Disorders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Cystic Fibrosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 5: World Historic Review for Cystic Fibrosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 6: World 15-Year Perspective for Cystic Fibrosis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Spinal Muscular Atrophy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 8: World Historic Review for Spinal Muscular Atrophy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 9: World 15-Year Perspective for Spinal Muscular Atrophy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Gaucher Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 11: World Historic Review for Gaucher Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 12: World 15-Year Perspective for Gaucher Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 13: World Recent Past, Current & Future Analysis for Tay-Sachs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 14: World Historic Review for Tay-Sachs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 15: World 15-Year Perspective for Tay-Sachs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Sickle Cell Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 17: World Historic Review for Sickle Cell Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 18: World 15-Year Perspective for Sickle Cell Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 19: World Recent Past, Current & Future Analysis for Other Disease Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 20: World Historic Review for Other Disease Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 21: World 15-Year Perspective for Other Disease Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for Molecular Screening Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 23: World Historic Review for Molecular Screening Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 24: World 15-Year Perspective for Molecular Screening Test by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 25: World Recent Past, Current & Future Analysis for Biochemical Screening Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 26: World Historic Review for Biochemical Screening Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 27: World 15-Year Perspective for Biochemical Screening Test by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 28: World Carrier Screening Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Carrier Screening by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Carrier Screening by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: World 15-Year Perspective for Carrier Screening by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Carrier Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 32: USA Recent Past, Current & Future Analysis for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: USA 15-Year Perspective for Carrier Screening by Disease Type - Percentage Breakdown of Value Sales for Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 35: USA Recent Past, Current & Future Analysis for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: USA 15-Year Perspective for Carrier Screening by Test Type - Percentage Breakdown of Value Sales for Molecular Screening Test and Biochemical Screening Test for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: Canada 15-Year Perspective for Carrier Screening by Disease Type - Percentage Breakdown of Value Sales for Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 41: Canada Recent Past, Current & Future Analysis for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Canada Historic Review for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: Canada 15-Year Perspective for Carrier Screening by Test Type - Percentage Breakdown of Value Sales for Molecular Screening Test and Biochemical Screening Test for the Years 2015, 2025 & 2030
  • JAPAN
    • Carrier Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 44: Japan Recent Past, Current & Future Analysis for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Japan Historic Review for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: Japan 15-Year Perspective for Carrier Screening by Disease Type - Percentage Breakdown of Value Sales for Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 47: Japan Recent Past, Current & Future Analysis for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Japan Historic Review for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: Japan 15-Year Perspective for Carrier Screening by Test Type - Percentage Breakdown of Value Sales for Molecular Screening Test and Biochemical Screening Test for the Years 2015, 2025 & 2030
  • CHINA
    • Carrier Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 50: China Recent Past, Current & Future Analysis for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: China Historic Review for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: China 15-Year Perspective for Carrier Screening by Disease Type - Percentage Breakdown of Value Sales for Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 53: China Recent Past, Current & Future Analysis for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: China Historic Review for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: China 15-Year Perspective for Carrier Screening by Test Type - Percentage Breakdown of Value Sales for Molecular Screening Test and Biochemical Screening Test for the Years 2015, 2025 & 2030
  • EUROPE
    • Carrier Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: Europe 15-Year Perspective for Carrier Screening by Disease Type - Percentage Breakdown of Value Sales for Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 59: Europe Recent Past, Current & Future Analysis for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Europe Historic Review for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: Europe 15-Year Perspective for Carrier Screening by Test Type - Percentage Breakdown of Value Sales for Molecular Screening Test and Biochemical Screening Test for the Years 2015, 2025 & 2030
    • TABLE 62: Europe Recent Past, Current & Future Analysis for Carrier Screening by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 63: Europe Historic Review for Carrier Screening by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: Europe 15-Year Perspective for Carrier Screening by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • FRANCE
    • Carrier Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 65: France Recent Past, Current & Future Analysis for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: France Historic Review for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: France 15-Year Perspective for Carrier Screening by Disease Type - Percentage Breakdown of Value Sales for Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 68: France Recent Past, Current & Future Analysis for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: France Historic Review for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: France 15-Year Perspective for Carrier Screening by Test Type - Percentage Breakdown of Value Sales for Molecular Screening Test and Biochemical Screening Test for the Years 2015, 2025 & 2030
  • GERMANY
    • Carrier Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 71: Germany Recent Past, Current & Future Analysis for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Germany Historic Review for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: Germany 15-Year Perspective for Carrier Screening by Disease Type - Percentage Breakdown of Value Sales for Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 74: Germany Recent Past, Current & Future Analysis for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Germany Historic Review for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: Germany 15-Year Perspective for Carrier Screening by Test Type - Percentage Breakdown of Value Sales for Molecular Screening Test and Biochemical Screening Test for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 77: Italy Recent Past, Current & Future Analysis for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Italy Historic Review for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: Italy 15-Year Perspective for Carrier Screening by Disease Type - Percentage Breakdown of Value Sales for Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 80: Italy Recent Past, Current & Future Analysis for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Italy Historic Review for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: Italy 15-Year Perspective for Carrier Screening by Test Type - Percentage Breakdown of Value Sales for Molecular Screening Test and Biochemical Screening Test for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Carrier Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 83: UK Recent Past, Current & Future Analysis for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: UK Historic Review for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: UK 15-Year Perspective for Carrier Screening by Disease Type - Percentage Breakdown of Value Sales for Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 86: UK Recent Past, Current & Future Analysis for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: UK Historic Review for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: UK 15-Year Perspective for Carrier Screening by Test Type - Percentage Breakdown of Value Sales for Molecular Screening Test and Biochemical Screening Test for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 89: Spain Recent Past, Current & Future Analysis for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Spain Historic Review for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: Spain 15-Year Perspective for Carrier Screening by Disease Type - Percentage Breakdown of Value Sales for Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 92: Spain Recent Past, Current & Future Analysis for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Spain Historic Review for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: Spain 15-Year Perspective for Carrier Screening by Test Type - Percentage Breakdown of Value Sales for Molecular Screening Test and Biochemical Screening Test for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 95: Russia Recent Past, Current & Future Analysis for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Russia Historic Review for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Russia 15-Year Perspective for Carrier Screening by Disease Type - Percentage Breakdown of Value Sales for Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 98: Russia Recent Past, Current & Future Analysis for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Russia Historic Review for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Russia 15-Year Perspective for Carrier Screening by Test Type - Percentage Breakdown of Value Sales for Molecular Screening Test and Biochemical Screening Test for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 101: Rest of Europe Recent Past, Current & Future Analysis for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Rest of Europe Historic Review for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: Rest of Europe 15-Year Perspective for Carrier Screening by Disease Type - Percentage Breakdown of Value Sales for Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 104: Rest of Europe Recent Past, Current & Future Analysis for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Rest of Europe Historic Review for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: Rest of Europe 15-Year Perspective for Carrier Screening by Test Type - Percentage Breakdown of Value Sales for Molecular Screening Test and Biochemical Screening Test for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Carrier Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: Asia-Pacific 15-Year Perspective for Carrier Screening by Disease Type - Percentage Breakdown of Value Sales for Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Asia-Pacific Historic Review for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: Asia-Pacific 15-Year Perspective for Carrier Screening by Test Type - Percentage Breakdown of Value Sales for Molecular Screening Test and Biochemical Screening Test for the Years 2015, 2025 & 2030
    • TABLE 113: Asia-Pacific Recent Past, Current & Future Analysis for Carrier Screening by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 114: Asia-Pacific Historic Review for Carrier Screening by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: Asia-Pacific 15-Year Perspective for Carrier Screening by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • AUSTRALIA
    • Carrier Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 116: Australia Recent Past, Current & Future Analysis for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Australia Historic Review for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: Australia 15-Year Perspective for Carrier Screening by Disease Type - Percentage Breakdown of Value Sales for Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 119: Australia Recent Past, Current & Future Analysis for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Australia Historic Review for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: Australia 15-Year Perspective for Carrier Screening by Test Type - Percentage Breakdown of Value Sales for Molecular Screening Test and Biochemical Screening Test for the Years 2015, 2025 & 2030
  • INDIA
    • Carrier Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 122: India Recent Past, Current & Future Analysis for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: India Historic Review for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: India 15-Year Perspective for Carrier Screening by Disease Type - Percentage Breakdown of Value Sales for Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 125: India Recent Past, Current & Future Analysis for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: India Historic Review for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: India 15-Year Perspective for Carrier Screening by Test Type - Percentage Breakdown of Value Sales for Molecular Screening Test and Biochemical Screening Test for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 128: South Korea Recent Past, Current & Future Analysis for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: South Korea Historic Review for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: South Korea 15-Year Perspective for Carrier Screening by Disease Type - Percentage Breakdown of Value Sales for Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 131: South Korea Recent Past, Current & Future Analysis for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: South Korea Historic Review for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: South Korea 15-Year Perspective for Carrier Screening by Test Type - Percentage Breakdown of Value Sales for Molecular Screening Test and Biochemical Screening Test for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 134: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of Asia-Pacific Historic Review for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: Rest of Asia-Pacific 15-Year Perspective for Carrier Screening by Disease Type - Percentage Breakdown of Value Sales for Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 137: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Rest of Asia-Pacific Historic Review for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: Rest of Asia-Pacific 15-Year Perspective for Carrier Screening by Test Type - Percentage Breakdown of Value Sales for Molecular Screening Test and Biochemical Screening Test for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Carrier Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Latin America 15-Year Perspective for Carrier Screening by Disease Type - Percentage Breakdown of Value Sales for Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 143: Latin America Recent Past, Current & Future Analysis for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Latin America Historic Review for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: Latin America 15-Year Perspective for Carrier Screening by Test Type - Percentage Breakdown of Value Sales for Molecular Screening Test and Biochemical Screening Test for the Years 2015, 2025 & 2030
    • TABLE 146: Latin America Recent Past, Current & Future Analysis for Carrier Screening by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 147: Latin America Historic Review for Carrier Screening by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: Latin America 15-Year Perspective for Carrier Screening by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 149: Argentina Recent Past, Current & Future Analysis for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Argentina Historic Review for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: Argentina 15-Year Perspective for Carrier Screening by Disease Type - Percentage Breakdown of Value Sales for Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 152: Argentina Recent Past, Current & Future Analysis for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Argentina Historic Review for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: Argentina 15-Year Perspective for Carrier Screening by Test Type - Percentage Breakdown of Value Sales for Molecular Screening Test and Biochemical Screening Test for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 155: Brazil Recent Past, Current & Future Analysis for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Brazil Historic Review for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: Brazil 15-Year Perspective for Carrier Screening by Disease Type - Percentage Breakdown of Value Sales for Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 158: Brazil Recent Past, Current & Future Analysis for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Brazil Historic Review for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: Brazil 15-Year Perspective for Carrier Screening by Test Type - Percentage Breakdown of Value Sales for Molecular Screening Test and Biochemical Screening Test for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 161: Mexico Recent Past, Current & Future Analysis for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Mexico Historic Review for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: Mexico 15-Year Perspective for Carrier Screening by Disease Type - Percentage Breakdown of Value Sales for Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 164: Mexico Recent Past, Current & Future Analysis for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Mexico Historic Review for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: Mexico 15-Year Perspective for Carrier Screening by Test Type - Percentage Breakdown of Value Sales for Molecular Screening Test and Biochemical Screening Test for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 167: Rest of Latin America Recent Past, Current & Future Analysis for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Rest of Latin America Historic Review for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 169: Rest of Latin America 15-Year Perspective for Carrier Screening by Disease Type - Percentage Breakdown of Value Sales for Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 170: Rest of Latin America Recent Past, Current & Future Analysis for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Rest of Latin America Historic Review for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 172: Rest of Latin America 15-Year Perspective for Carrier Screening by Test Type - Percentage Breakdown of Value Sales for Molecular Screening Test and Biochemical Screening Test for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Carrier Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 175: Middle East 15-Year Perspective for Carrier Screening by Disease Type - Percentage Breakdown of Value Sales for Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 176: Middle East Recent Past, Current & Future Analysis for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Middle East Historic Review for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 178: Middle East 15-Year Perspective for Carrier Screening by Test Type - Percentage Breakdown of Value Sales for Molecular Screening Test and Biochemical Screening Test for the Years 2015, 2025 & 2030
    • TABLE 179: Middle East Recent Past, Current & Future Analysis for Carrier Screening by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 180: Middle East Historic Review for Carrier Screening by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 181: Middle East 15-Year Perspective for Carrier Screening by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
  • IRAN
    • TABLE 182: Iran Recent Past, Current & Future Analysis for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Iran Historic Review for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 184: Iran 15-Year Perspective for Carrier Screening by Disease Type - Percentage Breakdown of Value Sales for Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 185: Iran Recent Past, Current & Future Analysis for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Iran Historic Review for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 187: Iran 15-Year Perspective for Carrier Screening by Test Type - Percentage Breakdown of Value Sales for Molecular Screening Test and Biochemical Screening Test for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 188: Israel Recent Past, Current & Future Analysis for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Israel Historic Review for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 190: Israel 15-Year Perspective for Carrier Screening by Disease Type - Percentage Breakdown of Value Sales for Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 191: Israel Recent Past, Current & Future Analysis for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Israel Historic Review for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 193: Israel 15-Year Perspective for Carrier Screening by Test Type - Percentage Breakdown of Value Sales for Molecular Screening Test and Biochemical Screening Test for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 194: Saudi Arabia Recent Past, Current & Future Analysis for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Saudi Arabia Historic Review for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 196: Saudi Arabia 15-Year Perspective for Carrier Screening by Disease Type - Percentage Breakdown of Value Sales for Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 197: Saudi Arabia Recent Past, Current & Future Analysis for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Saudi Arabia Historic Review for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 199: Saudi Arabia 15-Year Perspective for Carrier Screening by Test Type - Percentage Breakdown of Value Sales for Molecular Screening Test and Biochemical Screening Test for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 200: UAE Recent Past, Current & Future Analysis for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: UAE Historic Review for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 202: UAE 15-Year Perspective for Carrier Screening by Disease Type - Percentage Breakdown of Value Sales for Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 203: UAE Recent Past, Current & Future Analysis for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: UAE Historic Review for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 205: UAE 15-Year Perspective for Carrier Screening by Test Type - Percentage Breakdown of Value Sales for Molecular Screening Test and Biochemical Screening Test for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 206: Rest of Middle East Recent Past, Current & Future Analysis for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Rest of Middle East Historic Review for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 208: Rest of Middle East 15-Year Perspective for Carrier Screening by Disease Type - Percentage Breakdown of Value Sales for Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 209: Rest of Middle East Recent Past, Current & Future Analysis for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Rest of Middle East Historic Review for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 211: Rest of Middle East 15-Year Perspective for Carrier Screening by Test Type - Percentage Breakdown of Value Sales for Molecular Screening Test and Biochemical Screening Test for the Years 2015, 2025 & 2030
  • AFRICA
    • Carrier Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 212: Africa Recent Past, Current & Future Analysis for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Africa Historic Review for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 214: Africa 15-Year Perspective for Carrier Screening by Disease Type - Percentage Breakdown of Value Sales for Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 215: Africa Recent Past, Current & Future Analysis for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Africa Historic Review for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 217: Africa 15-Year Perspective for Carrier Screening by Test Type - Percentage Breakdown of Value Sales for Molecular Screening Test and Biochemical Screening Test for the Years 2015, 2025 & 2030

IV. COMPETITION